RE:RE:InterestingG1945V wrote: ARIMA11, Interesting how?
"We are excited about reaching this important milestone, which is a testament of the hard work that all our investigators, GOG leadership, team members and collaborators has put in, and are grateful to the patients that have participated in the study," said Dr. Sunil Gupta MBBS, FRCPC, Chief Medical Officer of OncoQuest Pharma US, Inc. (a subsidiary of CanariaBio Inc.) "We remain on track with our projected enrollment, and we are excited about the potential benefits that our drug may bring to patients with ovarian cancer."
How does OncoQuest Pharma US, Inc. fit in with OncoQuest Pharmaceuticals, Inc. ("OQP")
This is getting more and more confusing! You would think that QPT's CEO would issue a news update to clarify this web of confusion.
Who really owns " Oregovomab "?
G1945V
Oregovomab (Flora5) was sold to OQP which spinned off OQPBio (CanariBio).
As a result, QPT owns CAD$80M (convertible bonds) from OQPBio.
Hence, there is an indirect ownership positions from QPT.
If Flora5 performs, value of these bonds may go up.
If it does not the value can also go down.
Per MD&A
Quest received an in-kind dividend of OQP Bio bonds in January 2022. The dividend received by Quest has a face value of KRW129.1 billion (Cdn$135 million) and an estimated fair value on January 31, 2022, of Cdn$80.2 million
The issue now is for QPT to monetize those bonds. CanariBio does not have enough volume.
Also its a large sum of money so finding a buyer will not easy for QPT.
https://www.bloomberg.com/quote/016790:KS?sref=Vk28S8D7
https://canariabio.com/pharmaceutical-n-bio/ovarian-cancer-2/
https://canariabio.com/company/history/
https://www.flora-5.com
Again, suggest you talk to Pierre Vermette (CFO) of Quest Pharmatech.